Display Settings:

Format

Send to:

Choose Destination
    Biologics. 2010 Aug 9;4:187-97.

    Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma.

    Source

    Vanderbilt University Medical Center, Nashville, Tennessee, USA.

    Abstract

    Advanced renal cell carcinoma (RCC) remains a challenging, major health problem. Recent advances in understanding the fundamental biology underlying one form of RCC, ie, clear cell (or conventional) RCC, have opened the door to a series of targeted agents, such as the tyrosine kinase inhibitors (TKIs), which have become the standard of care in managing advanced clear cell RCC. Among the newest of these agents to receive Food and Drug Administration approval in this disease is pazopanib. This review will summarize what is known about the fundamental biology that underlies clear cell RCC, the data surrounding the previously approved targeted agents for this disease, including not only the TKIs but also the mTOR inhibitors and the vascular endothelial growth factor-specific agent, bevacizumab, and the newest TKI, pazopanib. It will also explore the potential role for pazopanib relative to the other available agents and where it may fit into the armamentarium for treatment of advanced/metastatic RCC.

    PMID:
    20714356
    [PubMed]
    PMCID:
    PMC2921256
    Free PMC Article

    Images from this publication.See all images (1) Free text

    Figure 1

      Supplemental Content

      Icon for Dove Medical Press Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk